Empasiprubart

N/A

Report date: 2026/05/09 20:00:18
First In Class

Base Information

Drug NameEmpasiprubart
Drug Alias NameARGX-117
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Complement C2
TargetsComplement C2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multifocal Motor NeuropathyDelayed Graft Function +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesArgenx SeBroteio Pharma BV
China Registration ClassN/A

Develop Information

Active CompaniesBroteio Pharma BVArgenx SeArgenx BV +[4] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Multifocal Motor NeuropathyDelayed Graft Function +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A